Concalls & earnings callsIPCA Laboratories Limited

Every summarised call, newest first. Latest is Q1 FY27, held 14 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.

Metric	This quarter	Change
Consolidated Revenue	₹2,788 Cr	21%
Consolidated EBITDA Margin	22.88%	4.49%
India Domestic Formulations Revenue	₹1,082 Cr	13%
India Chronic Segment Growth	17.2%	—

Latest guidance

Revised FY27 revenue growth guidance: 14% to 16% (up from 12-13%).
Revised FY27 consolidated EBITDA margin guidance: 23% (up from 22%).
Institutional generic business expected to be around INR 260 Cr to INR 300 Cr for the full year.
Capital expenditure for the current year: INR 700 Cr to INR 800 Cr.
Long-term EBITDA margin target for Ipca standalone: around 30%. Long-term consolidated target: 25-26%.

Said on the Q1 FY27 call.

Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

Quarter	Revenue	Net profit (PAT)	Basic EPS
Q3 FY25	₹2,245.37 Cr+9.4% YoY-4.7% QoQ	₹276.36 Cr+25% YoY+12.5% QoQ	₹9.78+37.9% YoY+8.1% QoQ
Q2 FY25	₹2,354.90 Cr+15.8% YoY+12.5% QoQ	₹245.75 Cr+80% YoY+23.4% QoQ	₹9.05+58.2% YoY+19.4% QoQ
Q1 FY25	₹2,092.63 Cr+31.8% YoY+2.9% QoQ	₹199.14 Cr+21.4% YoY+14872.9% QoQ	₹7.58+18.1% YoY+222.6% QoQ
Q4 FY24	₹2,033.01 Cr+34.5% YoY-1% QoQ	₹1.33 Cr-98.3% YoY-99.4% QoQ	₹2.35-22.2% YoY-66.9% QoQ
Q3 FY24	₹2,052.86 Cr+32.8% YoY+0.9% QoQ	₹221.00 Cr+101.4% YoY+61.9% QoQ	₹7.09+66.8% YoY+24% QoQ

Call history

14 Aug 2026
Q1 FY27Positive tone
Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.
Consolidated Revenue
₹2,788 Cr21%
Consolidated EBITDA Margin
22.88%4.49%
Pharmaceuticals & HealthcareVerified brief5 guidance items